Parkinson's disease (PD) is the second most common neurodegenerative illness majorly
affecting the population between the ages of 55 to 65 years. Progressive dopaminergic …

After fifteen years of genome-wide association studies (GWAS) in Parkinson's disease (PD),
what have we learned? Addressing this question will help catalogue the progress made …

Although over 90 independent risk variants have been identified for Parkinson's disease
using genome-wide association studies, most studies have been performed in just one …

Fundamentally, the identification of causes and contributors of disease represents the first
step in an etiology-based understanding of disease. This, in turn, is a required step in the …

Neuromelanin‐containing dopaminergic neurons in the substantia nigra pars compacta
(SNpc) are the most vulnerable neurons in Parkinson's disease (PD). Recent work suggests …

Introduction: Cerium oxide nanoparticles (CONPs) have been investigated for their
therapeutic potential in Parkinson's disease (PD) due to their potent and regenerative …

Background Recent studies have advanced our understanding of the genetic drivers of
Parkinson's disease (PD). Rare variants in more than 20 genes are considered causal for …

Introduction: There has been a bias in the existing literature on Parkinson's disease (PD)
genetics as most studies involved patients of European ancestry, mostly in Europe and …

Background A recently published East Asian genome‐wide association study of Parkinson;
s disease (PD) reported 2 novel risk loci, SV2C and WBSCR17. Objectives The objective of …

Abstract Advanced Parkinson's Disease (APD) is complicated by the emergence of motor
and non-motor fluctuations, which are initially predictable and eventually become …